ObjectiveTo master iodized salt monitoring results in Zhangjiakou city Hebei province,search problems in these monitoring results,and provide a basis for the development of control measures to iodine deficiency disorders.MethodsBy 2010,in Zhangjiakou city,nine salt samples were collected to detect the iodine level in each processing,packing and wholesale enterprise according to their orientation of east,west,north,south and center positions.In each county(district) with nine townships(towns,street offices) and more,nine townships (towns,street offices) were selected according to their east,west,south,north and center positions,in each township (town,street office ) selected,four villages (neighborhoods) were selected,eight residents per household in each village (neighborhood) chosen were selected,and an edible salt was collected in each household to test iodine level; in a county(district) with nine or less townships(towns,street offices),five townships(towns,district offices) were selected according to their east,west,south,north and center positions,four villages (neighborhoods) were selected,and 15 residents per household in each village(neighborhood) were selected to test the iodine level in an edible salt samples;after population-weighted calculation,indicators of iodized salt monitoring were calculated.ResultsA batch quality pass rate of processing,packing and wholesale enterprise was 100％(192/192); the rate of weighted non-iodized salt in a household was 0.04％(2/4932),iodized salt coverage rate was 99.96％ (4930/4932),iodized salt passing rate was 99.55％ (4908/4930),and qualified iodized salt coverage rate was 99.51％ (4908/4932).ConclusionsMonitoring indicators of iodized salt in Zhangjiakou city have reached the standand to eliminate iodine deficiency disorders.However,there still have unqualified iodized salt and non-iodized salt,and the monitoring and iodized salt market management should be strengthened.

Adult ; Facial Neoplasms ; diagnosis ; etiology ; pathology ; Fibroma ; diagnosis ; etiology ; pathology ; Forehead ; Hamartoma Syndrome, Multiple ; complications ; diagnosis ; pathology ; Humans ; Male ; Mouth Neoplasms ; diagnosis ; etiology ; Papilloma ; diagnosis ; etiology ; Skin Neoplasms ; diagnosis ; etiology ; pathology

Objectives: The aim of this study was to evaluate the effectiveness of aripiprazole long-acting injection in patients with schizophrenia undergoing antipsychotics combination therapy. Methods: We conducted a retrospective analysis using electronic medical records of patients with schizophrenia who initiated aripiprazole long-acting injectable and were treated with antipsychotics combination therapy. These patients were either admitted to a psychiatric hospital or treated as outpatients between June, 2019 and December, 2019. Results: Seventeen patients met the inclusion criteria. The mean number of antipsychotics significantly decreased from 2.53 use to 1.81 at month 12 (p=0.018). Total antipsychotics olanzapine equivalent dose significantly decreased from 46.96 to 27.54 at month 12 (p=0.005). The number of combined medications including antidepressants, mood stabilizers, anxiolytics, and anticholinergics did not significantly change. Both the Positive and Negative Syndrome Scale (PANSS) score and The Global Assessment of Functioning (GAF) score significantly improved until month 24 (p=0.004, 0.038; respectively). Conclusions This observational study confirmed that aripiprazole long-acting injection is an effective treatment option for patients with schizophrenia undergoing antipsychotic combination therapy. Well-controlled clinical trials are necessary in the near future.

Objectives: The aim of this study was to evaluate the effectiveness of aripiprazole long-acting injection in patients with schizophrenia undergoing antipsychotics combination therapy. Methods: We conducted a retrospective analysis using electronic medical records of patients with schizophrenia who initiated aripiprazole long-acting injectable and were treated with antipsychotics combination therapy. These patients were either admitted to a psychiatric hospital or treated as outpatients between June, 2019 and December, 2019. Results: Seventeen patients met the inclusion criteria. The mean number of antipsychotics significantly decreased from 2.53 use to 1.81 at month 12 (p=0.018). Total antipsychotics olanzapine equivalent dose significantly decreased from 46.96 to 27.54 at month 12 (p=0.005). The number of combined medications including antidepressants, mood stabilizers, anxiolytics, and anticholinergics did not significantly change. Both the Positive and Negative Syndrome Scale (PANSS) score and The Global Assessment of Functioning (GAF) score significantly improved until month 24 (p=0.004, 0.038; respectively). Conclusions This observational study confirmed that aripiprazole long-acting injection is an effective treatment option for patients with schizophrenia undergoing antipsychotic combination therapy. Well-controlled clinical trials are necessary in the near future.

Objectives: The aim of this study was to evaluate the effectiveness of aripiprazole long-acting injection in patients with schizophrenia undergoing antipsychotics combination therapy. Methods: We conducted a retrospective analysis using electronic medical records of patients with schizophrenia who initiated aripiprazole long-acting injectable and were treated with antipsychotics combination therapy. These patients were either admitted to a psychiatric hospital or treated as outpatients between June, 2019 and December, 2019. Results: Seventeen patients met the inclusion criteria. The mean number of antipsychotics significantly decreased from 2.53 use to 1.81 at month 12 (p=0.018). Total antipsychotics olanzapine equivalent dose significantly decreased from 46.96 to 27.54 at month 12 (p=0.005). The number of combined medications including antidepressants, mood stabilizers, anxiolytics, and anticholinergics did not significantly change. Both the Positive and Negative Syndrome Scale (PANSS) score and The Global Assessment of Functioning (GAF) score significantly improved until month 24 (p=0.004, 0.038; respectively). Conclusions This observational study confirmed that aripiprazole long-acting injection is an effective treatment option for patients with schizophrenia undergoing antipsychotic combination therapy. Well-controlled clinical trials are necessary in the near future.

Early life adversities together with genetic predispositions have been associated with elevated risks of neuropsychiatric disorders during later life. In order to investigate the underlying mechanisms, many chronic, early-life stress paradigms in multiple animal models have been developed. Previously, studies reported that maternal separation (MS) in the early postnatal stages triggers depression-and/or anxiety-like behaviors in rats. However, similar studies using mice have reported inconsistent behavioral outcomes. In this study, we sought to assess behavioral outcomes from two different early-life stress paradigms; a conventional 3-hour MS and a maternal separation with early weaning (MSEW) paradigm using C57BL/6J male mice with independent cohorts. Our data demonstrated that both MS and MSEW paradigms did not produce reported behavioral anomalies. Therefore, MS paradigms in mice require further validation and modification.
Animals ; Anxiety ; Cohort Studies ; Depression ; Genetic Predisposition to Disease ; Humans ; Male ; Mice* ; Models, Animal ; Rats ; Weaning

OBJECTIVES: Previous studies have shown that the endogenous opioid system, which plays an important role in drinking behavior, might be related to the genetic etiology of alcohol dependence. And a recent study reported that the affinity of micro opioid receptor, which is closely related to the endogenous opioid system activity, is affected by the genotype of micro opioid receptor gene (OPRM1) A118G. The present study examined the association of the genotype of OPRM1 A118G with alcohol dependence in Koreans. METHODS: The author studied the genotype of OPRM1 A118G in 112 Korean patients with alcohol dependence and 140 healthy Korean control subjects. RESULTS: 1) A statistically significant increase in A/G or G/G genotype of OPRM1 A118G was observed in patients with alcohol dependence (67.0%) compared to the controls (51.4%). 2) Among patients with alcohol dependence, no significant difference in OPRM1 A118G polymorphism was observed relative to the age at which drinking started, the age of onset of alcohol-related problems, the age of first admission to psychiatric hospital for alcohol-related problems, the family history of alcohol dependence in the first-degree relatives or of severe alcohol withdrawal symptoms. But the frequency of A/G or G/G genotypes of OPRM1 A118G was significantly higher in those who drank 17 days or more per month in the previous year (80.8%) than in those with fewer days of drinking (56.5%). CONCLUSION: These results suggest that A/G or G/G genotypes of micro opioid receptor gene A118G are important genetic factors in the etiology of alcohol dependence.
Age of Onset ; Alcoholism* ; Drinking ; Drinking Behavior ; Genotype* ; Hospitals, Psychiatric ; Humans ; Receptors, Opioid ; Substance Withdrawal Syndrome

In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.